New Stock News | Excellent Vision Plan is expected to have its IPO in Hong Kong as soon as this year with a valuation of up to 3 billion US dollars.
According to reports, Beijing-based GigaAI is reportedly considering conducting its first initial public offering (IPO) in Hong Kong as early as this year.
According to reports, GigaAI, headquartered in Beijing, is discussing the possibility of conducting its first public offering (IPO) in Hong Kong as soon as this year. The founder and CEO of GigaAI, Huang Guan, stated in an interview during the World Artificial Intelligence Conference in Shanghai that a new round of financing is about to be completed, with the company's valuation reaching $3 billion, bringing it one step closer to going public. He mentioned that this would make GigaAI the highest-valued world model startup company in China. World models can better represent and predict the movement of humans and objects using artificial intelligence.
Huang Guan said, "Globally, we will be the first company among world model startups to go public."
However, when asked if they have hired a sponsor for the IPO and investment bank, Huang Guan did not give a direct response.
Established in 2023, GigaAI is the first technology company in China to focus on "world models". Founder Huang Guan holds a Ph.D. in Automation from Tsinghua University and has worked at top institutions such as Microsoft Asia Research Institute and Samsung China Research Institute. The core team consists of members from renowned institutions globally such as Tsinghua, Peking University, Chinese Academy of Sciences, CMU, as well as companies like Microsoft, Samsung, Horizon Robotics, Baidu, Bosch, etc.
From March to June 2026, GigaAI completed three rounds of financing in three months, totaling 3.5 billion RMB. Investors include top institutions such as Lion City Capital of Singapore, Zhongbei Fund, Jiantu Investments, Huawei Habo, Zhongjin Capital, BAIC Investment, and others.
Related Articles

Tianbao Energy (01671) proposes to appoint Yin Qi as an executive director, chairman of the board, and chairman of the nomination committee.

"Reckitt Benckiser (LLY.US) weight loss drug advertisements face legal action! Accused by Novo Nordisk A/S Sponsored ADR Class B (NVO.US) of 'misleading marketing'"

Shanghai Shen Lian Biomedical Corporation (688098.SH): The swine pseudorabies live vaccine (strain JS-A1) has obtained the approval number for veterinary drug products.
Tianbao Energy (01671) proposes to appoint Yin Qi as an executive director, chairman of the board, and chairman of the nomination committee.

"Reckitt Benckiser (LLY.US) weight loss drug advertisements face legal action! Accused by Novo Nordisk A/S Sponsored ADR Class B (NVO.US) of 'misleading marketing'"

Shanghai Shen Lian Biomedical Corporation (688098.SH): The swine pseudorabies live vaccine (strain JS-A1) has obtained the approval number for veterinary drug products.

RECOMMEND





